Following the vadadustat CRL issued on March 30, 2022, Akebia hosted a call with investors to discuss the steps forward. Below FENIX provides highlights and insights from the call, including readthrough to GSK’s daprodustat.

If you receive our email blasts, you already have an account. Log in now

Context counts when making decisions.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

About The Author

Matthew Maryniak

|

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account. Log in now

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Akebia announced the FDA has issued a CRL regarding the vadadustat NDA for the treatment of anemia due to CKD. According to the press release, FDA concluded that the data in the NDA “do not support a favorable benefit-risk assessment of vadadustat for dialysis and non-dialysis patients.” FDA expressed safety concerns including failure to meet non-inferiority in MACE in the non-dialysis patient population, increased risk of thromboembolic events, driven by vascular access thrombosis in dialysis patients, and the risk of drug-induced liver injury. Additionally, in the CRL, FDA suggested that Akebia investigate ways to potentially demonstrate a favorable benefit-risk assessment through new clinical trials. Akebia will be working with its partners to evaluate the CRL, and it intends to request a meeting with FDA to evaluate next steps. Importantly, Akebia will host a conference call Wednesday, March 30 at 6:00 PM ET to discuss the CRL.

If you receive our email blasts, you already have an account. Log in now

Context counts when making decisions.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

About The Author

Matthew Maryniak

|

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account. Log in now

Purchase Blast$599.00

You can read the article’s full content online after purchase.